Market Trends of France Ultrasound Devices Industry
This section covers the major market trends shaping the France Ultrasound Devices Market according to our research experts:
High-intensity Focused Ultrasound Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Focused ultrasonic energy can be utilized to treat a variety of solid tumours because it is a non-invasive approach for tissue ablation. High-intensity focused ultrasound is being utilised more frequently to treat both primary and metastatic tumours because it can accurately identify tumours for ablation. Factors such as increasing cancer prevalence and initiatives by key players are expected to increase the market growth. In 2020, France recorded 467,965 new cancer cases, while there were 1,501,881 new cases of cancer overall. Globocan 2020 predicted that by 2040, there will be roughly 579,388 new cancer cases in France. Increased use of high-intensity focused ultrasound systems for the diagnosis will result from the country's increasing number of new cancer cases, which is anticipated to propel this market's expansion in France over the course of the projected period.
High-intensity ultrasound products from several major market players are being introduced in France, which will increase the use of HIFU systems. For instance, THERACLION, a forward-thinking French company that specializes in echotherapy (using HIFU or High-Intensity Focused Ultrasound) treatment, received the CE Mark for the second generation of SONOVEIN, its HIFU varicose vein treatment option, in October 2020. Increased acceptance of HIFU systems in this region is anticipated to fuel the growth of this market in France as a result of the key players' increasing initiatives by releasing their products in the treatment of varicose veins to provide patients access to non-invasive varicose vein treatments. Future market expansion is anticipated to be fueled by rising research activities on high-intensity ultrasound systems for the treatment of various illnesses as well as approvals from the French health authorities. For instance, in August 2020, EDAP TMS SA will launch a Phase II multicenter clinical trial evaluating its Focal One HIFU for the management of deep rectal endometriosis with permission from the French Ministry of Health. This Phase II multicenter trial will assess safety and efficacy in a single patient group of 38 women with a confirmed diagnosis of deep rectal endometriosis in a total of five major French hospitals. This will lead to increased research activities on HIFU systems for different ailments and result in the adoption of HIFU systems for different diseases, thereby expected to drive the market growth in France.
Hence, the above developments pertaining to high-intensity focused ultrasound systems, it is expected to drive market growth in the country.
